Biochemical prognostic factors and risk of relapses in patients with cervical cancer

Gynecologic Oncology

Volumn 107, Issue 1 SUPPL., 2007, Pages

  Gadducci, Angiolo ^a   Tana, Roberta ^a   Fanucchi, Antonio ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; HUMAN; LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TUMOR VOLUME; UTERINE CERVIX CANCER;

ANTIGENS, NEOPLASM; CA-125 ANTIGEN; FEMALE; HUMANS; KERATINS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SERPINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34748841024     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.033     Document Type: Conference Paper

References (56)

1. Ballesta A.M., Torre C.G., Bombardieri E., Gion M., and Molina R. Up dating on tumor markers in tissues and in biological fluids. Basic aspects and clinical applications (1993), Edizioni Minerva Medica, Torino
2. Lehtovirta P., Viinikka L., and Ylikorkala O. Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix. Gynecol Oncol 37 (1990) 276-278
3. Duk J.M., Groenier K.H., de Bruijn H.W., Hollema H., ten Hoor K.A., van der Zee A.G., et al. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 14 (1996) 111-118
4. Scambia G., Panici P.B., Baiocchi G., Amoroso M., Foti E., Greggi S., et al. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol 164 (1991) 631-636
5. Gadducci A., Ferdeghini M., Caenaro G.F., Prontera C., Malagnino G., Annicchiarico C., et al. Immunoacidic protein (IAP) as marker for cervical and endometrial carcinoma: alone and in comparison with CA125 and SCC. Cancer J 5 (1992) 272-278
6. Avall-Lundqvist E.H., Sjovall K., Nilsson B.R., and Eneroth P.H. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur J Cancer 28A (1992) 1695-1702
7. Gocze P.M., Vahrson H.W., and Freeman DA. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix. Oncology 51 (1994) 430-434
8. Kainz C., Sliutz G., Mustafa G., Bieglmayr C., Koelbl H., Reinthaller A., et al. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer. Gynecol Oncol 56 (1995) 402-405
9. Ngan H.Y., Cheung A.N., Lauder I.J., Wong L.C., and Ma H.K. Prognostic significance of serum tumour markers in carcinoma of the cervix. Eur J Gynaecol Oncol 17 (1996) 512-517
10. Massuger L.F., Koper N.P., Thomas C.M., Dom K.E., and Schijf C.P. Improvement of clinical staging in cervical cancer with serum squamous cell cervical carcinoma antigen and CA 125 determinations. Gynecol Oncol 64 (1997) 473-476
11. Abe A., Nakano T., Morita S., and Oka K. Clinical evaluation of serum and immunohistological expression of SCC and CA19-9 in radiation therapy for cervical cancer. Anticancer Res 19 (1999) 829-836
12. Micke O., Prott F.J., Schafer U., Tangerding S., Potter R., and Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 20 (2000) 5113-5115
13. Pras E., Willemse P.H., Canrinus A.A., de Bruijn H.W., Sluiter W.J., ten Hoor K.A., et al. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Radiat Oncol Biol Phys 52 (2002) 23-32
14. Takeda M., Sakuragi N., Okamoto K., Todo Y., Minobe S., Nomura E., et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand 81 (2002) 451-457
15. Ohara K., Tanaka Y., Tsunoda H., Nishida M., Sugahara S., and Itai Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet Gynecol 100 (2002) 781-787
16. Maiman M., Feuer G., Fruchter R.G., Shaw N., and Boyce J. Value of squamous cell carcinoma antigen levels in invasive cervical carcinoma. Gynecol Oncol 34 (1989) 312-316
17. Scambia G., Benedetti Panici P., Foti E., Ferrandina G., Leone F.P., Marciano M., et al. Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome. Eur J Cancer 32A (1996) 259-263
18. Bae S.N., Namkoong S.E., Jung J.K., Kim C.J., Park J.S., Kim J.W., et al. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 64 (1997) 418-424
19. Gaarenstroom K.N., Bonfrer J.M., Korse C.M., Kenter G.G., and Kenemans P. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. Anticancer Res 17 (1997) 2955-2958
20. Bolger B.S., Dabbas M., Lopes A., and Monaghan J.M. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol 765 (1997) 309-313
21. Callet N., Cohen-Solal Le Nir C.C., Berthelot E., and Pichon M.F. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations. Eur J Gynaecol Oncol 19 (1998) 50-56
22. Hong J.H., Tsai C.S., Chang J.T., Wang C.C., Lai C.H., Lee S.P., et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 41 (1998) 823-830
23. Gaarenstroom K.N., Kenter G.G., Bonfrer J.M.G., Korse C.M., Van de Vijver M.J., Fleuren G.J., et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?. Gynecol Oncol 77 (2000) 164-170
24. Molina R., Filella X., Auge J.M., Bosch E., Torne A., Pahisa J., et al. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res 25 (2005) 1765-1771
25. Gadducci A., Scambia G., Benedetti Panici P., Ferdeghini M., Battaglia F., Caenaro G.F., et al. The prognostic relevance of pretreatment serum immunosuppressive acidic protein (IAP) in patients with squamous cell carcinoma of the uterine cervix: a comparison with squamous cell carcinoma antigen (SCC). Cancer J 7 (1994) 241-252
26. Sproston A.R., Roberts S.A., Davidson S.E., Hunter R.D., and West C.M. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. Br J Cancer 72 (1995) 1536-1540
27. Yuan C.C., Wang P.H., Ng H.T., Tsai L.C., Juang C.M., and Chiu L.M. Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. Eur J Gynaecol Oncol 23 (2002) 17-20
28. Takeshima N., Hirai Y., Katase K., Yano K., Yamauchi K., and Hasumi K. The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer. Gynecol Oncol 68 (1998) 263-266
29. Yoon S.M., Shin K.H., Kim J.Y., Seo S.S., Park S.Y., Kang S., et al. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy. Int. J. Gynecol. Cancer. 17 (2007) 872-878
30. Bonfrer J.M., Gaarenstroom K.N., Korse C.M., Van Bunningen B.N., and Kenemans P. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Anticancer Res 17 (1997) 2329-2334
31. Strauss H.G., Laban C., Lautenschlager C., Buchmann J., Schneider I., and Koelbl H. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer 38 (2002) 1987-1991
32. Pectasides D., Economides N., Bourazanis J., Pozadzizou P., Gogou L., Koutsiouba P., et al. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer. Am J Clin Oncol 17 (1994) 307-312
33. Dodd J.K., Henry R.J., Tyler J.P., and Houghton C.R. Cervical carcinoma: a comparison of four potential biochemical tumor markers. Gynecol Oncol 32 (1989) 248-252
34. Ngan H.Y., Cheng G.T., Yeung W.S., Wong L.C., and Ma H.K. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix. Gynecol Oncol 52 (1994) 63-68
35. Esajas M.D., Duk J.M., de Bruijn H.W.A., Aalders J.G., Willemse P.H.B., Sluiter W.W., et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 19 (2001) 3960-3966
36. Chan Y.M., Ng T.Y., Ngan H.Y., and Wong L.C. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective?. Gynecol Oncol 84 (2002) 7-11
37. Shirato H., Ichimura W., Wakushima H., Nishioka T., and Suzuki K. Squamous cell carcinoma antigen in serum for monitoring of head and neck and uterine cervical squamous cell carcinomas after radiotherapy. Acta Oncol 32 (1993) 663-666
38. Niibe Y., Kazumoto T., Toita T., Yamazaki H., Higuchi K., Ii N., et al. Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecol Oncol 103 (2006) 435-438
39. Chang W.C., Hung Y.C., Lin C.C., Shen Y.Y., and Kao C.H. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels-a preliminary report. Cancer Invest 22 (2004) 180-184
40. Chang T.C., Law K.S., Hong J.H., Lai C.H., Ng K.K., Hsueh S., et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies. A phase II study. Cancer 101 (2004) 164-171
41. Sakurai H., Suzuki Y., Nonaka T., Ishikawa H., Shioya M., Kiyohara H., et al. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy-tumor volume and FDG uptake value. Gynecol Oncol 100 (2006) 601-607
42. Lai C.H., Yen T.C., and Chang T.C. Positron emission tomography imaging for gynecologic malignancy. Curr Opin Obstet Gynecol 19 (2007) 37-41
43. Ferdeghini M., Gadducci A., Annicchiarico C., Prontera C., Malagnino G., Castellani C., et al. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res 13 (1993) 1841-1844
44. Tsai S.C., Kao C.H., and Wang S.J. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. Neoplasma 43 (1996) 27-29
45. Suzuki Y., Nakano T., Ohno T., Abe A., Morita S., and Tsujii H. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. J Cancer Res Clin Oncol 126 (2000) 332-336
46. Bonfrer J.M., Gaarenstroom K.N., Kenter G.G., Korse C.M., Hart A.A., Gallee M.P., et al. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol 55 (1994) 371-375
47. Puthucode-Easwaran S., Naik R., Athavale R., Handley G., Lopes A., Godfrey K., et al. Comparison of pre-treatment CYFRA 21-1 and SCC-Antigen assay in primary cervical carcinoma-a preliminary report. J Obstet Gynaecol 25 (2005) 486-488
48. Jacobs I., and Bast Jr. R. The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod 4 (1989) 1-12
49. Duk M., Aalders J.G., Fleuren G.J., Krans M., and De Bruijn H.W. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol 73 (1989) 661-668
50. Ngan H.Y., Cheung A.N., Lauder I.J., Cheng D.K., Wong L.C., and Ma H.K. Tumour markers and their prognostic value in adenocarcinoma of the cervix. Tumour Biol 19 (1998) 439-444
51. Bender D.P., Sorosky J.I., Buller R.E., and Sood A.K. Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am J Obstet Gynecol 189 (2003) 113-117
52. Leminen A. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. Gynecol Oncol 39 (1990) 358-363
53. Borras G., Molina R., Xercavins J., Ballista A., and Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol 57 (1995) 205-211
54. Tsai C.C., Liu Y.S., Huang E.Y., Huang S.C., Chang H.W., Tseng C.W., et al. Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. Gynecol Oncol 100 (2006) 591-595
55. Tabata T., Takeshima N., Tanaka N., Hirai Y., and Hasumi K. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tumour Biol 21 (2000) 375-380
56. Niloff J.M., Klug T.L., Schaetzl E., Zurawski Jr. V.R., Knapp R.C., and Bast Jr. RC. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148 (1984) 1057-1058